Why IMU is a multi multi bagger, page-28192

2025 ASCO Gastrointestinal Cancers Symposium
Save the date taking place from 23 until 25 January 2025 San Francisco.
Mid-December 2024: Abstract titles and Press Program announced.
Abstracts accepted will be released at 5:00 PM ET on January 21, 2025.
Late-Breaking Abstracts (LBAs) will be released at 7:00 AM (PT) on their day of presentation at the Symposium.

Expecting an ASX announcement any day now, confirming a poster presentation for the above symposium event.

City of Hope presented January 2024.

"Dr Daneng Li, from the City of Hope National Comprehensive Cancer Centre presented the
poster which detailed background on CF33, the MAST study design, objectives and results
observed to date.
Conclusions of the poster presentation included:
• Preliminary data from the first three dose levels demonstrates encouraging anti
tumor activity with CF33-hNIS monotherapy, including one patient with
cholangiocarcinoma, treated intratumorally, who achieved an immunological
complete response (CR) with no known recurrence after one year.
• CF33-hNIS monotherapy may be an effective and safe treatment option for GI
(gastrointestinal) malignancies and warrants further investigation in biliary tract
cancer patients.
• Immunological changes in CF33-hNIS responding patients show a robust innate and
adaptive immune response known to promote anti-tumor immunity and
underscores the immunomodulatory potential of this therapy".

Regards.